Topic: BioTech

Brain Canada & CQDM fund AbCellera’s cell screening platform technology

AbCellera Biologics Inc and the Univ of British Columbia (UBC) received non-dilutive funding of $1 million from pharma-based consortium CQDM and charitable organization Brain Canada Foundation to advance a discovery platform for next-generation antibody therapeutics. With the additional contribution of $450,000 from AbCellera, the program will leverage AbCellera’s high throughput, single-cell screening platform to allow rapid…

CCRM and the Univ of Queensland partner to commercialize neutropenia treatment

The Univ of Toronto-hosted Centre for the Commercialization of Regenerative Medicine (CCRM) has struck a licensing deal with the UniQuest, the commercialization arm of Brisbane AU-based Univ of Queensland (UQ) to commercialize a treatment for chemotherapy-induced neutropenia. The treatment, developed by researchers at UQ’s Australian Institute for Bioengineering and Nanotechnology, provides a therapeutic dose of…

Microbion Corp received US$25 million in venture funding

Vancouver and Bozeman MT-based -based Microbion Corp has received US$25-million in venture capital to further develop its lead compound for the treatment of antibiotic-resistant infections. The funding is being provided by the Global Health Sciences Venture Fund, a US$500-million joint venture between Vancouver’s Quark Venture Inc and GF Securities, a Hong Kong-based investment bank. The…